Abstract
Against this background, the aim of the present study is to evaluate the polygenic impact on platelet reactivity in patients treated with clopidogrel in a group of patients with ACS treated at Méderi. The central hypothesis of this project is that it is possible to identify genetic risk factors in a population with a heterogeneous and unique gene pool such as our population. The proposed work will be the first comprehensive approach to study the impact of polymorphisms in various genes associated with the response to clopidogrel. We propose to perform this approach using a robust platform such as next-generation sequencing, population genetic analysis, and the construction of a polygenic risk score using multiple SNP analysis related to therapeutic response. Relevantly, this study may identify novel phenotype-related variants that can be proposed after functional validation as novel alleles and incorporated into worldwide databases such as CYP The Human Cytochrome P450 Allele Nomeclature (http://www.cypalleles.ki.se/).
Translated title of the contribution | Pharmacogenomic analysis by next generation sequencing (NGS) for estimation of polygenic involvement in platelet reactivity in patients treated with clopidogrel |
---|---|
Original language | Spanish (Colombia) |
Pages | 1-1 |
Number of pages | 1 |
State | Submitted - Sep 12 2023 |
Event | V congreso Latinoamericano de Farmacogenomica y Medicina Personalizada - Duration: Sep 6 2023 → Sep 12 2023 |
Seminar
Seminar | V congreso Latinoamericano de Farmacogenomica y Medicina Personalizada |
---|---|
Period | 9/6/23 → 9/12/23 |
All Science Journal Classification (ASJC) codes
- Genetics